科研动态PubMed 摘要

术前立体定向放射外科对比术中铯-131近距离治疗用于切除后脑转移瘤:系统综述与荟萃分析。

PubMed 白名单日捞 · 2026-11-09

完整摘要 · 中文译文

背景:术前立体定向放射外科(SRS)和术中铯-131(Cs-131)近距离放射治疗是切除脑转移瘤(BMs)术后SRS的替代方案。随机3期Radiation One and Done研究(ROADS;NCT04365374)显示,与术后立体定向放射治疗相比,Cs-131粒子可改善手术床控制,但相对于术前SRS的结局尚未明确。 方法:检索PubMed、Embase和ScienceDirect至2026年10月(PRISMA 2020);通过其他方法又识别出一项试验。提取初治BMs的12个月局部控制(LC)、软脑膜疾病(LMD)、放射性坏死(RN)和总生存(OS)。采用随机效应广义线性混合模型合并比例,并以亚组差异检验进行比较;敏感性分析包括meta回归、Hartung-Knapp、留一法、随访和分割分析。 结果:共纳入15项术前SRS研究(918例患者/940个BMs)和4项近距离放射治疗研究(207例患者/217个BMs)。合并12个月LC为Cs-131近距离放射治疗97%(95% CI 90-99),术前SRS为90%(86-93)(亚组差异检验p = 0.054;meta回归p = 0.019;Hartung-Knapp p = 0.066);在报告观察计数的研究中,LC为99% vs. 90%(p = 0.009)。在术前SRS中,大分割治疗后的LC为96%,单次分割治疗后为86%(p = 0.005)。LMD(9.1% vs. 5.1%)和RN(0.7% vs. 5.2%)无显著差异。近距离放射治疗的中位OS为15.6个月 apy(范围5.9-42.5;11.0个月,范围5.9-20.1,排除ROADS估计值)以及术前SRS为14.4个月(范围6.3-26.4)。 结论:两种方法均实现了高局部控制率(LC),且软脑膜播散(LMD)和放射性坏死(RN)发生率低。Cs-131近距离放疗的LC有高于术前SRS的趋势(97% vs. 90%;p = 0.054),在报告观察计数的研究中差异显著(99% vs. 90%;p = 0.009)。大分割术前SRS获得的LC与近距离放疗相似,提示该差异可能反映的是单次分割剂量降阶,而非任一 modality 的内在优势。这两种技术可能发挥互补作用,有必要开展前瞻性比较研究。 注册:本综述未在PROSPERO注册。

完整摘要 · 英文原文

BACKGROUND: Pre-operative stereotactic radiosurgery (SRS) and intraoperative cesium-131 (Cs-131) brachytherapy are alternatives to post-operative SRS for resected brain metastases (BMs). The randomized phase 3 Radiation One and Done Study (ROADS; NCT04365374) showed improved surgical-bed control with Cs-131 tiles versus post-operative stereotactic radiotherapy, but outcomes relative to pre-operative SRS are undefined. METHODS: PubMed, Embase, and ScienceDirect were searched through October 2026 (PRISMA 2020); one further trial was identified by other methods. Twelve-month local control (LC), leptomeningeal disease (LMD), radiation necrosis (RN), and overall survival (OS) were extracted for treatment-naïve BMs. Proportions were pooled with random-effects generalized linear mixed models and compared with a test for subgroup differences; sensitivity analyses included meta-regression, Hartung-Knapp, leave-one-out, follow-up, and fractionation analyses. RESULTS: Fifteen pre-operative SRS studies (918 patients/940 BMs) and four brachytherapy studies (207 patients/217 BMs) were included. Pooled 12-month LC was 97% (95% CI 90-99) with Cs-131 brachytherapy and 90% (86-93) with pre-operative SRS (test for subgroup differences p = 0.054; meta-regression p = 0.019; Hartung-Knapp p = 0.066); among studies reporting observed counts, LC was 99% vs. 90% (p = 0.009). Within pre-operative SRS, LC was 96% after hypofractionated and 86% after single-fraction treatment (p = 0.005). LMD (9.1% vs. 5.1%) and RN (0.7% vs. 5.2%) did not differ significantly. Median OS was 15.6 months with brachytherapy (range 5.9-42.5; 11.0 months, range 5.9-20.1, excluding the ROADS estimate) and 14.4 months with pre-operative SRS (range 6.3-26.4). CONCLUSION: Both approaches achieved high LC with low rates of LMD and RN. There was a trend towards higher LC with Cs-131 brachytherapy than with pre-operative SRS (97% vs. 90%; p = 0.054), and significantly so among studies reporting observed counts (99% vs. 90%; p = 0.009). Hypofractionated pre-operative SRS achieved LC similar to that of brachytherapy, suggesting that the difference may reflect single-fraction dose de-escalation rather than an intrinsic advantage of either modality. The two techniques may serve complementary roles, and prospective comparative study is warranted. REGISTRATION: This review was not registered in PROSPERO.

English
Pre-operative stereotactic radiosurgery versus intraoperative cesium-131 brachytherapy for resected brain metastases: a systematic review and meta-analysis.
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界